miR-484 targets MYCBP2, a member of the c-Myc oncogene family that plays a role in CRC pathogenesis37 and miR-605 targets SMAD4, a TGF-β1 family member whose upregulation is often associated with aggressive CRC8. Here, TGFB1 is linked to colorectal carcinoma.